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Background: Despite most liver transplants in North America being from deceased donors, the number of
living donor liver transplants has increased over the last decade. Although outcomes of liver retransplantation after deceased donor liver transplantation have been widely published, outcomes of
retransplant after living donor liver transplant need to be further elucidated.
Method: We aimed to compare waitlist outcomes and survival post-retransplant in recipients of initial
living or deceased donor grafts. Adult liver recipients relisted at University Health Network between
April 2000 and October 2020 were retrospectively identiﬁed and grouped according to their initial graft:
living donor liver transplants or deceased donor liver transplant. A competing risk multivariable model
evaluated the association between graft type at ﬁrst transplant and outcomes after relisting. Survival
after retransplant waitlisting (intention-to-treat) and after retransplant (per protocol) were also
assessed. Multivariable Cox regression evaluated the effect of initial graft type on survival after
retransplant.
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Results: A total of 201 recipients were relisted (living donor liver transplants, n ¼ 67; donor liver
transplants, n ¼ 134) and 114 underwent retransplant (living donor liver transplants, n ¼ 48; deceased
donor liver transplants, n ¼ 66). The waitlist mortality with an initial living donor liver transplant was
not signiﬁcantly different (hazard ratio ¼ 0.51; 95% conﬁdence interval, 0.23e1.10; P ¼ .08). Both unadjusted and adjusted graft loss risks were similar post-retransplant. The risk-adjusted overall intentionto-treat survival after relisting (hazard ratio ¼ 0.76; 95% conﬁdence interval, 0.44e1.32; P ¼ .30) and per
protocol survival after retransplant (hazard ratio:1.51; 95% conﬁdence interval, 0.54e4.19; P ¼ .40) were
equivalent in those who initially received a living donor liver transplant.
Conclusion: Patients requiring relisting and retransplant after either living donor liver transplants or
deceased donor liver transplantation experience similar waitlist and survival outcomes.
© 2022 Elsevier Inc. All rights reserved.

Introduction
The incidence of liver retransplantation ranges from 5% to 22% of
all liver transplants (LTs), as it remains the only curative option for
recurrent liver failure.1,2 Notwithstanding the opportunity cost to
potential ﬁrst-time transplant candidates on the waiting list, the
outcomes after retransplant in recipients receiving a deceased
donor liver graft during initial transplant are acceptable despite
increased technical challenge, higher transfusion requirements, a
more protracted postoperative course, and greater health care
costs.2e5
Although a predominant majority of LTs performed in the West
are deceased donor LTs (DDLTs), the use of living donor LTs (LDLTs)
has increased in the last decade.6,7 For recipients, results of LDLT are
similar to outcomes using donation after brain death (DBD) and
donation after circulatory death (DCD) grafts.8e11 With regard to
retransplantation, a registry study of the United States using data
from the Organ Procurement and Transplantation Network/United
Network for Organ Sharing (OPTN/UNOS) noted that short-term
(1-year) outcomes for recipients who initially received LDLT are
similar to retransplant after DDLT.12 Currently, however, there
remains a lack of granular data on outcomes after relisting for
patients who have received an LDLT during their ﬁrst transplant.
Considering the relatively high rate of waitlist dropout for patients
awaiting retransplant, waitlist outcomes as well as long-term outcomes after retransplant need to be clariﬁed.
For recipients undergoing a primary LT with either an LDLT or
DDLT allograft, we sought to evaluate and compare waitlist outcomes and survival, from intention-to-treat [ITT] (ie, after relisting
for LT) and per protocol (ie, for those achieving retransplant)
standpoints at a center performing a relatively high volume of both
LDLTs and DDLTs. The intent for this information was to aid in
counseling patients listed for retransplant. In considering sickness
at the time of original transplant and etiologies for retransplant, it
was hypothesized that waitlist and survival outcomes of retransplant after original LDLT would be superior to those after DDLT.

type of graft received at initial LT: LDLT or DDLT. All retransplants
except 1 were performed using grafts from deceased donors. Patients who were <18 years at their initial transplant (n ¼ 5) received
an initial LT at an outside institution (n ¼ 9), underwent a multiorgan transplant at the time of the initial LT (n ¼ 2), or underwent a
multiorgan transplant at their retransplant (n ¼ 9) were excluded.
This study complies with the Strengthening the Reporting of
Observational studies in Epidemiology (STROBE) guidelines for
retrospective studies.13 Figure 1 is a STROBE-compliant diagram
highlighting all patients who were included and excluded.
Covariates

This study was approved by our institutional ethics review
board ( #19e5564), and a waiver of informed consent was
obtained.

We recorded sex; age, at relisting and retransplant; body mass
index (BMI), at relisting and retransplant; blood group; etiology of
liver disease (hepatitis C virus [HCV] and hepatitis B virus, cryptogenic cirrhosis, alcohol-related liver disease, primary sclerosing
cholangitis/primary biliary cirrhosis/autoimmune hepatitis,
nonalcoholic steatohepatitis, and other); laboratory Model for EndStage Liver Disease (MELD) score (at initial LT, relisting, and
retransplant); exception points at relisting; and time on the waitlist
(from relisting). Donor variables included donor sex, age, and the
relation of the donor to the recipient. Operative variables for both
index and retransplant included details of the caval anastomosis
(piggyback or caval replacement), biliary reconstruction, type and
amount of blood products transfused (packed red blood cells
[PRBCs], in milliliters; fresh frozen plasma [FFP], in milliliters;
platelets, in milliliters; and cell saver, in milliliters), estimated
blood loss, in milliliters; cold ischemia time (CIT), in minutes; warm
ischemia time (WIT), in minutes; and graft type (including right or
left lobe for LDLT, DCD, DBD, and split for DDLT). Postoperative
variables for both index and retransplant included details about
complications (biliary leak, stricture, or other biliary complication),
vascular thrombosis (portal vein thrombosis and hepatic artery
thrombosis), unplanned operations related to the LT itself, rejection, graft nonfunction, acute renal failure, need for dialysis, duration of postoperative dialysis in days, number of intensive care days,
and length of stay in days. Reasons for graft failure included disease
recurrence, graft nonfunction, vascular thrombosis (hepatic artery
thrombosis [early (before 30 days) or late (after 30 days)] or portal
vein thrombosis). When clinically relevant, data points were
obtained at both the initial LT and relisting time points.

Study population

Complications

We assessed patients who were relisted for LT between April
2000 and October 2020 at our institution. The start date of the
study period was chosen as to coincide with the start of the LDLT
program at a North American center doing a high volume of both
LDLTs and DDLTs. At the time of analysis, patient data were up to
date as of January 23, 2021. Patients were grouped according to the

Complications were recorded according to the Clavien-Dindo
classiﬁcation (excluding grade I complications) in various time
intervals post-retransplant: complications to discharge, discharge
to 3 months, 3 to 6 months, 6 to 12 months, and 12 to 24 months.14
Transfusion was only recorded once within each time interval (ie,
regardless of how many postoperative transfusions a patient

Methods
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Figure 1. Strengthening the Reporting of Observational studies in Epidemiology diagram of cohorts, included and excluded.

received it was only captured once as a grade II complication within
a given interval). At each time interval, a complication score
according to the comprehensive complication index (CCI) was
calculated.15

Listing criteria
Before December 2012 at our center, the allocation of organs
was based on the CanWAIT approach, which prioritized patients
according to their location (intensive care unit, hospital ﬂoor, or
home) as well as the severity of their liver disease. After December
2012, the MELD-based allocation system was adopted.16 Patients
with a failed live donor/DCD graft (provided that they were transplanted within accepted criteria and graft failure occurred because
of biliary and/or vascular complications) received MELD exception
points. A baseline of 22 points were awarded, followed by a 3-point
increase every 90 days up to 40 points.17 Patients are deemed
urgent status in cases of acute liver failure and retransplant for
primary nonfunction of hepatic artery thrombosis 7 days of the
ﬁrst transplant (4F if intubated or 3F if not requiring mechanical

ventilation*).17 These patients receive ﬁrst priority with national
sharing of organs.17,18
Outcome measures
The 2 study groups, LDLT and DDLT, were based on the type of
graft received at the initial transplant. The study’s end points were
waitlist mortality after relisting, patient survival after relisting for
LT (ITT), patient and graft survival for those achieving retransplant
(per protocol), and complications post-retransplant up to 24
months.
Waitlist mortality was deﬁned as either death on the waitlist or
dropout from the waitlist because of medical deterioration or unsuitability. Graft loss was deﬁned as (1) need for repeat retransplant
or (2) death due to liver failure. The date of graft loss was therefore
deﬁned as the date of the repeat retransplant or the date of death if
the date of death was due to graft-related causes. Deaths from
causes other than liver failure were not deﬁned as graft failure. A
sensitivity analysis for graft survival was also performed with death
censoring (where graft loss was deﬁned as retransplant or death
due to any cause).
Statistical analysis

*

Candidates that urgently need an organ are designated as 4F or 3F in the Canadian organ allocation system (https://www.giftoﬂife.on.ca/resources/pdf/
healthcare/TP-9-100.pdf).

Descriptive data were expressed using medians and interquartile range (IQR) and compared using the Mann-Whitney U test.
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Categorical variables were expressed using numbers and percentages and compared using the c2 and Fischer exact test. Multivariable Poisson regression with robust variance and linear regression
models were constructed to evaluate the association of graft type
with Clavien-Dindo grade IIIb and the CCI from retransplant up to
3 months, respectively. To assess waitlist outcomes, instead of the
Kaplan-Meier method, which censors for the competing event of
transplant, a cumulative incidence approach was used to account
for the presence of a competing risk of transplant with waitlist
mortality.19 The cumulative incidence was estimated using subdistribution estimates for each cause. To assess the effect of the
exposure (graft type at initial LT), a cause-speciﬁc competing-risk
multivariable model was constructed for hazard of waitlist mortality and retransplant. Similarly, for the evaluation of graft failure,
causes of death due to causes other than those related to the graft
itself were considered competing events for graft loss (need for reretransplant or death due to liver failure). Graft-related reasons
included portal vein thrombosis, liver failure, graft failure: other,
recurrent disease, recurrent HCV, graft failure: hepatitis, hepatic
artery thrombosis, cirrhosis, and graft failure: primary. Nonegraftrelated reasons included hepatocellular carcinoma recurrence,
multisystem organ failure, cerebral bleed, myocardial infarction,
unknown, sepsis, cardiac arrest, respiratory failure, de novo cancers, ischemic small bowel, cancer, hemorrhagic shock, cardiac arrest, acute respiratory distress syndrome, and renal failure. These
were also analyzed using cause-speciﬁc Cox models. ITT patient
survival was evaluated from the time of relisting to death or last
known follow-up. On the per protocol analysis, patient and graft
survival was evaluated in those who received retransplant. All
survival estimates used the Kaplan Meier method, and group
comparisons were made with log-rank tests. Additional sensitivity
analyses were performed stratifying by graft type at initial transplant and receipt of exception points at relisting and a separate
analysis separating the DDLT group into deceased after circulatory
death and deceased after brain death donation.
Multivariable Cox regression was performed to evaluate the
association between graft type at the initial transplant and mortality after re-listing for LT. Variables included in the model for ITT
survival included etiology of primary liver disease; reason for graft
failure after the initial LT; recipient sex, age, BMI, dialysis requirement, MELD score, and exception points, all at relisting; time between the ﬁrst LT and relisting; and year of ﬁrst listing. Variables
included in the multivariable model for the sub-distribution hazard
of waitlist mortality and transplantation were the same as those
included in the ITT model. The variables included in the model for
graft failure included etiology of primary liver disease; reason of
graft failure after the initial LT; recipient sex, age, BMI, dialysis
requirement, MELD score, and exception points, all at retransplant;
CIT; WIT; time between primary LT and relisting; and year of ﬁrst
listing. Variables included in the model for per protocol survival
were the same as those included in the graft failure model.
Statistical analyses were performed using R, version 4.0.3 (R
Foundation for Statistical Computing, Vienna, Austria). The
competing risk analysis with the cumulative incidence function
was performed using the package cmprsk, version 2.2-10.20 Robust
error variance for the Poisson model was computed using the
package, sandwich, version 3.0-1,21,22 which were applied to the
marginal Wald tests using the package, lmtest, version 0.9-38.23
Results
Study population and index liver transplantation
A total of 201 recipients relisted for transplant met the study
inclusion criteria (graft at ﬁrst transplant LDLT, n ¼ 67, and DDLT,

n ¼ 134; Figure 1). Of the 721 total primary LDLTs in the study
period, 67 (9%) were relisted and of the 1,957 total primary DDLTs in
the study period, 134 (7%) were relisted. Upon relisting, 48 underwent retransplant in the initial LDLT group and 66 underwent
retransplant in the initial DDLT group. Five of the patients included
who received a retransplant were also retransplanted at a later
stage (ie, repeat retransplant) and received a total of 3 grafts (n ¼ 2
in the LDLT group and n ¼ 3 in the DDLT group). The LDLT group had
lower biologic MELD scores at the ﬁrst LT (median [IQR] LDLT ¼ 16
[12e21] vs DDLT ¼ 19 [13e26]; P ¼ .048) and a higher proportion of
Roux-en-Y biliary reconstructions (LDLT ¼ 45 [67%] vs DDLT ¼ 35
(27%); P < .001). Biliary complications (n ¼ 23 [34%]) and early (<30
days) hepatic artery thrombosis (n ¼ 20 [30%]) were the most
common reasons for graft failure after LDLT and were more common in these patients than in the initial DDLT group (P < .001). The
most common cause of DDLT graft failure was disease recurrence
(n ¼ 33 [25%]) and rejection (n ¼ 26 [19%]; Table S1). Retransplant
and relisting characteristics are shown in Table 1 and Table S2,
respectively.
Waitlist outcomes after relisting
The cumulative incidence of waitlist mortality at both 90 days
(LDLT ¼ 3.0% [95% conﬁdence interval {CI}, 0.6e9.3] vs DDLT ¼
17.2% [95% CI, 11.3e24.0]; P ¼ .004) and 1 year (LDLT ¼ 9.0% [95% CI,
3.6e17.4] vs DDLT ¼ 28.4% [95% CI, 21.0e36.2]; P ¼ .002) postrelisting was lower in the LDLT group (Figure 2A). After multivariable adjustment, patients initially receiving a DDLT had a similar of
waitlist mortality (reference [ref]: DDLT, LDLT cause-speciﬁc hazard
ratio [HR] ¼ 0.51; 95% CI, 0.23e1.10; P ¼ .08) (Table 2).
The cumulative incidence of LT after relisting was similar between the groups at 90 days (LDLT ¼ 38.8% [95% CI, 27.1e50.3] vs
DDLT ¼ 29.1% [95% CI, 21.6e37.0]; P ¼ .11) and 1 year (LDLT ¼ 55.2%
[95% CI, 42.4e66.3] vs DDLT ¼ 43.3% [95% CI, 34.7e51.5]; P ¼ .08)
(Figure 2B). After multivariable adjustment, initially receiving an
LDLT was not associated with an increased incidence of retransplant after relisting (ref: DDLT, LDLT cause-speciﬁc HR ¼ 1.44; 95%
CI, 0.94e2.20; P ¼ .10) (Table 2).
Intention-to-treat survival from relisting
The median ITT survival was 4.3 years in the DDLT group and 7.2
years in the LDLT group. The ITT survival was higher in the LDLT
group at 1 year (DDLT ¼ 64.0% [95% CI, 56.4e72.7] vs LDLT ¼ 82.7%
[95% CI, 73.9e92.6]; P ¼ .005) (Figure 3, Figure S1, and Table S3).
After multivariable adjustment, the ITT mortality hazard was not
statistically signiﬁcantly different between the groups (ref: DDLT;
LDLT HR ¼ 0.76, 95% CI, 0.44e1.32; P ¼ .30]) (Table 3).
Complications after retransplant
There was no difference in the proportions of dialysis requirement, machine ventilation, or intensive care location at re-LT between the groups (Table 1). There was no difference in intensive
care unit stay, total length of hospital stay, need for postretransplant dialysis, or duration of dialysis post-retransplant between the groups. Moreover, the total complication scores (CCIs)
and the proportion of Clavien-Dindo grade IIIb were overall
similar between the groups after retransplant, with the exception
of a higher proportion of Clavien-Dindo grade IIIb after retransplant between 6 and 12 months in the group that had undergone an
initial transplant with an LDLT graft (0 vs 17%; P < .001) (Tables S4
and S5).
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Table I
Retransplant characteristics

Age at re-LT, y, median (IQR)
BMI at re-LT, median (IQR)
Blood type, n (%)
A
B
AB
O
MELD at re-LT, median (IQR)
Receipt of exception points at relisting, n (%)
Dialysis at re-LT, n (%)
Machine ventilation at re-LT, n (%)
Intensive care unit at re-LT, n (%)
Graft type at re-LT, n (%)
DCD
LDLT
NDD
Donor age, y, median (IQR)
Donor age 60, n (%)
PRBC transfusion intraoperatively, mL, median (IQR)
FFP transfusion intraoperatively, mL, median (IQR)
PLT transfusion intraoperatively, mL, median (IQR)
Cell saver transfusion intraoperatively, mL, median (IQR)
EBL, mL, median (IQR)
Roux-en-Y biliary reconstruction, n (%)
Piggyback technique, n (%)
CIT at re-LT, min, median (IQR)
CIT 6 and <12 h at re-LT, n (%)
CIT 12 h at re-LT, n (%)
WIT at re-LT, min, median (IQR)

DDLT (n ¼ 66)

LDLT (n ¼ 48)

P value

54 (45e59)
24.6 (21.7e27.3)

53 (43e60)
24.8 (22.7e27.7)

.98
.60
.18

27 (41)
12 (18)
4 (6)
23 (35)
25 (18e32)
5 (8)
11 (20)
10 (15)
15 (23)

24 (50)
12 (25)
0 (0)
12 (25)
20 (16e24)
21 (44)
6 (15)
9 (19)
17 (35)

2 (3)
1 (2)
63 (96)
39 (22e50)
9 (14)
1,500 (1,000e2,500)
1,800 (900e3,600)
200 (0e509)
500 (233e1,555)
2,500 (2000e5,000)
44 (68)
6 (13)
472 (373e 570)
45 (68)
5 (8)
46 (40e53)

0
0 (0)
48 (100)
39 (23e52)
7 (15%)
1,000 (500e2,125)
1,200 (350e2,000)
64 (0e320)
460 (208e750)
2,100 (1,450e4,100)
36 (77)
7 (17)
381 (311e491)
26 (57)
2 (4)
45 (39e52)

.003
< .001
.56
.60
.15
.33

.65
.89
.02
.01
.45
.26
.37
.30
.54
.01
.21
.49
.51

BMI, body mass index; CIT, cold ischemia time; DCD, deceased after circulatory death donation; DDLT, deceased donor liver
transplant; EBL, estimated blood loss; FFP, fresh frozen plasma; IQR, interquartile range; LDLT, living donor liver transplant;
MELD, Model for End-Stage Liver Disease; NDD, donor after neurologic determination of death; PLT, platelet; PRBC, packed red
blood cell; re-LT, retransplant; WIT, warm ischemia time.

Figure 2. The 90-day cumulative incidence of (A) waitlist mortality and (B) retransplant from relisting by graft type at ﬁrst transplant.

Per protocol survival after retransplant
The median per protocol survival was not reached in either
the DDLT group or the LDLT group. The 90-day and 1-, 3-, 5-,
and 10-year per protocol survival was not statistically signiﬁcantly different between the groups (Figure S2 and Table S6).
After multivariable adjustment, the per protocol mortality hazard was not statistically signiﬁcantly different between the

groups (ref: DDLT; LDLT HR ¼ 1.51; 95% CI, 0.54e4.19; P ¼ .40])
(Table 3).
Graft failure after retransplant
The cumulative incidence of graft failure after retransplant was
similar between the LDLT and DDLT groups (Figure S3). Similarly,
the cumulative incidence of death due to nonegraft-related
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Table II
Effect of graft type at ﬁrst transplant (live donor liver transplant versus deceased
donor liver transplant) on waitlist outcomes after relisting
Outcome (cause-speciﬁc hazard)

Waitlist mortality*
LDLT
Transplant*
LDLT

Overall (reference: DDLT)

Table III
Effect of graft type at ﬁrst transplant (LDLT v DDLT) on intention-to-treat and per
protocol survival from relisting and retransplant, respectively
Outcome

Cause-speciﬁc HR (95% CI)

P value

0.51 (0.23e1.10)

.08

1.44 (0.94e2.20)

.10

Reference: DDLT

P value

Overall
HR (95% CI)

CI, conﬁdence interval; DDLT, deceased donor liver transplant; HR, hazard ratio;
LDLT, live donor liver transplant; LT, liver transplant; MELD, Model for End-Stage
Liver Disease.
*
Adjusted for time between primary transplant and relisting, reason of graft
failure after initial LT, age at relisting, MELD score at relisting, exception points
awarded at relisting, and year of relisting.

Figure 3. Intention-to-treat survival from relisting stratiﬁed by graft type at the ﬁrst
transplant.

reasons was similar between the LDLT and DDLT groups (Figure S4).
On sensitivity analysis, death-censored graft survival postretransplant was similar between the groups (P ¼ .50) (Figure S5).
After risk-adjustment, there was no statistically signiﬁcant difference in graft loss (ref: DDLT; LDLT cause-speciﬁc HR ¼ 1.33; 95% CI,
0.32e5.47; P ¼ .69) or death due to nonegraft-related reasons (ref:
DDLT; LDLT cause-speciﬁc HR ¼ 0.91; 95% CI, 0.34e2.42; P ¼ .85)
between the groups (Table S7).

Sensitivity analyses
Survival and waitlist outcomes based on initial graft type and
receipt of exception points are shown in Figures S6eS11.

Discussion
After relisting for LT, the waitlist outcomes are similar in patients undergoing an LDLT at their ﬁrst transplant compared with
those who had received a DDLT. Speciﬁcally, on both ITT survival
from relisting and per protocol survival (from retransplant), similar
outcomes were noted between groups. Additionally, the risk of
graft loss after retransplant was noted to be equivalent between
patients who received either an LDLT or DDLT as their ﬁrst
transplant.

Intention to treat*
LDLT
Per protocoly
LDLT

0.76 (0.44e1.32)

.30

1.51 (0.54e4.19)

.40

BMI, body mass index; CI, conﬁdence interval; CIT, cold ischemia time; DDLT,
deceased-donor liver transplant; HR, hazard ratio; LDLT, live donor liver transplant;
LT, liver transplant; MELD; Model for End-Stage Liver Disease; WIT, warm ischemia
time.
*
Adjusted for etiology of liver disease, reason of graft failure after the initial LT,
recipient sex, age at relisting, BMI at relisting, MELD score at relisting, dialysis
requirement at relisting, exception points awarded at relisting, time between primary transplant and relisting, and year of ﬁrst listing.
y
Adjusted for etiology of liver disease, reason of graft failure after the initial LT,
BMI at re-LT, recipient age at re-LT, MELD at re-LT, exception points awarded at
relisting, CIT, WIT, packed red blood cell transfusion (in milliliters), dialysis
requirement at relisting, time between primary LT and relisting, and year of re-LT.

Similar to after DDLT, ~10% of LDLT recipients require retransplant.24e26 Patient and graft survival after retransplant has historically been inferior to survival after primary LT, although outcomes
for retransplant have improved over time.5,25,27 These improvements result from progress in perioperative care, immunosuppression, and better treatment of HCV.28,29 Another consideration
of retransplant is the associated higher cost relative to primary LT.30
Nonetheless, the present consensus does not consider previous
receipt of a scarce medical resource, such as a graft, as a criterion for
future distribution of the same resource.31e34 Instead, organs are
distributed based on the sickness of the patient and the likelihood
of beneﬁt they can derive from the transplant.34,35
Understanding the outcomes of waitlisted patients provides
insight into whether the present allocation of organs effectively
prioritizes certain groups of patients as well as clinically meaningful data that allow informed counseling of potential recipients
on expected survival once relisted. A prior study evaluating waitlist
mortality by Bitterman et al12 noted similar outcomes between the
retransplant groups (initial LDLT ¼ 18.9% vs initial DDLT ¼ 22.2%;
P ¼ .192). In the present report, the waitlist dropout due to death for
the initial LDLT group was 15% (10/67) and for the DDLT group 37%
(50/134). To further understand this, we evaluated survival from
the time of relisting as an ITT analysis. The purpose of this analysis
was to capture the survival of the cohort of patients who are unable
to undergo a retransplant due to waitlist dropout. Compared with
DDLT, the LDLT group had a similar 5-year, 10-year, and overall ITT
survival. Although patients who develop graft failure after LDLT
requiring retransplant received prioritization (assuming they were
transplanted within accepted criteria and graft failure occurred
because of biliary and/or vascular complications), the present system seems equitable in that outcomes between the 2 groups were
equivalent. Furthermore, it should be taken into account that patients undergoing LDLT have not yet had a negative effect on the
waiting list and in fact have increased organ availability for other
patients awaiting their ﬁrst transplant. After risk-adjustment,
including adjustment for receipt of exception points at relisting,
the LDLT group had a similar risk of waitlist mortality and transplant as the DDLT group. Although not explored explicitly in this
study, it is feasible to perform retransplantation using living donor
grafts, which we have previously described.36 The option of
retransplantation using LDLT may be an option in select patients,
such as those with stable MELD scores with clear deterioration on
the waitlist as manifested by progressive weight loss, sarcopenia,
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need for frequent paracenteses, etc. Further, the potential donor
should have an ideal graft (age <50, nonsteatotic, ABO-compatible,
and with a graft-recipient weight ratio >1). Challenges around the
use of living donor grafts for retransplantation include the higher
potential risk associated with complex vascular reconstructions as
well as concerns for small-for-size syndrome, the sequelae of which
may be particularly detrimental for patients who are critically ill
and have a relatively higher metabolic demand than primary LT
recipients.
Patients who receive a primary LT with a living donor graft have
distinct advantages over patients who receive a DDLT, as they are
typically less sick and often more conditioned at the time of LT,
experience shorter wait times, and have potential to receive a
higher-quality graft.37 They were, however, more frequently
retransplanted for hepatic artery thrombosis and biliary complications. Compared with prior studies, 1- and 5-year survival outcomes were similar for retransplant after an initial LDLT (1-year
University Health Network [UHN] ¼ 86.7% vs Adult-to-Adult Living
Donor Liver Transplantation Cohort Study [A2ALL] ¼ 86%; 5-year
UHN ¼ 64.5% vs A2ALL ¼ 64%).24 In the OPTN/UNOS registry
analysis by Bitterman et al,12 the odds of 1-year mortality after
retransplant was similar between patients with either an initial
LDLT or DDLT (odds ratio ¼ 0.74; 95% CI, 0.51e1.08). One of the
strengths of this study is that it offers a longer-term follow-up (up
to 10 years) of survival from retransplant for patients with initial
LDLT and DDLT and reports that for patients who can undergo a
second transplant, the survival from retransplant is similar.
This study is limited by its retrospective and nonrandomized
study design, with the potential for selection and misclassiﬁcation
bias. We attempted to limit the potential effect of selection bias by
analyzing the ITT outcomes from the time patients were relisted for
a broad-spectrum view on relisted LDLT and DDLT patients. Nonetheless, as a result of the single-institutional study design, results
may not be generalizable to other centers. However, a singleinstitutional study design can overcome some of the substantial
differences and variability in listing/transplanting practices that
multicenter/large database studies are more likely to be subject to.
The high volume of both DDLTs and LDLTs performed at this single
center in North America make the data distinct and well suited for
addressing the study’s aims. Lastly, although multivariable adjustment for potential confounders was performed, the potential for
residual confounding and type I error remains.
In conclusion, patients who require relisting and retransplant
after either LDLT or DDLT experience similar waitlist outcomes, ITT
survival from relisting, per protocol survival from retransplant,
complications after retransplant, and incidence of graft loss after
retransplant.
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